For research use only. Not for therapeutic Use.
MG-2119 is a potent monomeric tau and α-syn aggregation inhibitor. MG-2119 is a potential agent for neurological disorders research[1].
| Catalog Number | I044425 |
| CAS Number | 1065500-40-4 |
| Synonyms | 6-[(2-methoxyacetyl)amino]-3-(2-phenylethyl)-N-(2-pyridin-3-yloxypropyl)benzimidazole-4-carboxamide |
| Molecular Formula | C27H29N5O4 |
| Purity | ≥95% |
| InChI | InChI=1S/C27H29N5O4/c1-19(36-22-9-6-11-28-16-22)15-29-27(34)23-13-21(31-25(33)17-35-2)14-24-26(23)32(18-30-24)12-10-20-7-4-3-5-8-20/h3-9,11,13-14,16,18-19H,10,12,15,17H2,1-2H3,(H,29,34)(H,31,33) |
| InChIKey | BQOOSSSSVKDEIO-UHFFFAOYSA-N |
| SMILES | CC(CNC(=O)C1=C2C(=CC(=C1)NC(=O)COC)N=CN2CCC3=CC=CC=C3)OC4=CN=CC=C4 |
| Reference | [1]. Gabr MT, et al. Dual Targeting of Monomeric Tau and α-Synuclein Aggregation: A New Multitarget Therapeutic Strategy for Neurodegeneration. ACS Chem Neurosci. 2020;11(14):2051-2057. |
